Ohcanbohtosat - Kathleen Schostack
- Čájehuvvo 1 - 3 / 3
-
1
Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer Dahkki Hong Yang, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, William D. Bradley, Richard J. Lee, Kathleen Schostack, Mary Ellen Simcox, Scott Kopetz, David Heimbrook, Brian Lestini, Gideon Bollag, Fei Su
Almmustuhtton 2011Artigo -
2
RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models Dahkki Hong Yang, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, Zenaida Go, Raman Iyer, Stanley P. Kolis, Sylvia Zhao, Richard Lee, Joseph F. Grippo, Kathleen Schostack, Mary Ellen Simcox, David Heimbrook, Gideon Bollag, Fei Su
Almmustuhtton 2010Artigo -
3
Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation Dahkki Fei Su, William D. Bradley, Qiongqing Wang, Hong Yang, Lizhong Xu, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, Min Jung Kim, Kerstin Trunzer, Richard J. Lee, Kathleen Schostack, Jade Carter, Thomas Albert, Søren Germer, Jim Rosinski, Mitchell Martin, Mary Ellen Simcox, Brian Lestini, David Heimbrook, Gideon Bollag
Almmustuhtton 2011Artigo
Ohcanreaiddut:
Laktáseaddji fáttát
Biology
Cancer research
Kinase
MAPK/ERK pathway
Melanoma
Biochemistry
Cancer
Cell biology
Gene
Genetics
Internal medicine
KRAS
Medicine
Metastatic melanoma
Mutation
PI3K/AKT/mTOR pathway
Signal transduction
V600E
Vemurafenib
Cetuximab
Colorectal cancer
Epidermal growth factor receptor
Erlotinib
In vivo
MEK inhibitor
Pharmacology
Phosphorylation
Protein kinase A
Protein kinase B